ID   G361/R
AC   CVCL_IW13
DR   cancercelllines; CVCL_IW13
DR   Wikidata; Q54835390
RX   PubMed=26365896;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_90295; PLX-4720 (PLX4720).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.242_243CC>TT (-138/-139CC>TT); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1220 ! G-361
SX   Male
AG   31Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 19-12-24; Version: 12
//
RX   PubMed=26365896; DOI=10.1016/j.molonc.2015.08.003; PMCID=PMC4717845;
RA   Baenke F., Chaneton B., Smith M., van den Broek N.J.F., Hogan K.,
RA   Tang H.-R., Viros A., Martin M., Galbraith L., Girotti M.R., Dhomen N.,
RA   Gottlieb E., Marais R.;
RT   "Resistance to BRAF inhibitors induces glutamine dependency in
RT   melanoma cells.";
RL   Mol. Oncol. 10:73-84(2016).
//